免疫细胞素Hu14.18-IL-2对黑色素瘤病人的免疫激活作用

目的评估免疫细胞素Hu14.18-IL-2对黑色素瘤病人体内免疫作用。方法33位黑色素瘤病人用一种人源化抗神经节苷脂GD-2的单抗与IL-2融合的免疫细胞素进行治疗,按每天0.8、1.6、3.2、4.8、6.0、7.5 mg/m2静脉滴注,连续3 d为一疗程,病情稳定或缓解后,在第5周接受第2疗程治疗。观察病人外周血单核淋巴细胞抗体依赖的细胞毒性、自然杀伤细胞活性、IL-2的体外增殖以及IL-2可溶性受体的变化。结果Hu14.18-IL-2能诱导病人淋巴细胞的吞噬作用,增强外周血中自然杀伤细胞的杀伤能力和数目,使血清中IL-2受体复合体的可溶性受体α链水平上升。结论免疫细胞素Hu14.18-IL-2对黑色素瘤病人具有免疫激活作用。

Immune Activation of Immunocytokine Hu14.18-IL-2 in Patients with Melanoma

Objective To evaluate the in vivo immune activation of immunocytokine Hu14.18-IL-2 in the patients with melanoma.Methods Thirty-three patients were treated with Hu14.18-IL2,a humanized anti-GD-2 McAb linked to IL-2,by intravenous drip for 3 d as the 1st course at dosages of 0.8,1.6,3.2,4.8,6.0 and 7.5 mg/m2 respectively.The patients received the 2nd course of treatment at the 5th week after stabilization or remission of disease.The peripheral blood mononuclear cell(PBMC) antibody-dependent cytotoxicity,NK cell activity as well as in vitro proliferation and soluble receptor of IL-2 of patients before and after treatment were observed.Results Hu14.18-IL-2 induced the phagocytosis of lymphocytes,enhanced the killing activity of NK cells in peripheral blood and increased the level of soluble alpha chain of IL-2 receptor complex in sera.Conclusion Hu14.18-IL-2 showed immune activation in patients with melanoma.